FATE analyst estimates

Fate Therapeutics (FATE) analyst ratings, the average price target and its range, and every firm's latest call.

FATE analyst ratings and price targets

DateFirmCallTarget
Aug 14, 2026Wells FargoFate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo$3.50
Aug 14, 2026Piper SandlerFate Therapeutics price target raised to $8 from $6 at Piper Sandler$8.00
Jun 8, 2026H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)$7.00
May 19, 2026JefferiesFate Therapeutics assumed with a Buy at Jefferies$4.00
Mar 6, 2025Stifel NicolausFate Therapeutics price target lowered to $3 from $5 at Stifel$3.00
Nov 13, 2024BMO CapitalFate Therapeutics (FATE) PT Lowered to $5 at BMO Capital$5.00
Aug 14, 2024Stifel NicolausFate Therapeutics (FATE) PT Lowered to $5 at Stifel$5.00
Jun 17, 2024Piper SandlerPiper Sandler Upgrades Fate Therapeutics (FATE) to Overweight$6.00
May 16, 2024H.C. WainwrightFate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright$5.00
May 10, 2024Canaccord GenuityFate Therapeutics price target lowered to $9 from $11 at Canaccord$9.00
May 10, 2024BMO CapitalFate Therapeutics (FATE) PT Lowered to $6 at BMO Capital$6.00
May 10, 2024Piper SandlerFate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler$4.00
Jan 9, 2023Goldman SachsGoldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4$4.00
Jan 6, 2023Piper SandlerPiper Sandler Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $12$12.00
Jan 6, 2023Morgan StanleyMorgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8$8.00